DOI: 10.21276/sajp.2019.8.5.12

Pages: 257-262

Although canagliflozin has been successfully used for the treatment of type 2 diabetes since its introduction in 2013, it has been continuing in research for the treatment of various diseases. The most common form of diabetes is type 2 diabetes and it was found that 95% of the people were suffering from this disease. Therefore, this review covers the pharmacokinetics and pharmacological effects of canagliflozin. It is hoped that this review will open the new gateways of research to achieve new rational approaches for more potent, less toxic and more therapeutically effective agents using canagliflozin.